[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562005":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":40,"collaborators":10,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":10,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":57,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Diagnosis of advanced hepatobiliary malignancies",null,"Patients diagnosis of advanced hepatobiliary malignancies require immunotherapy or combination immunotherapy after evaluation according to clinical guidelines",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Jiajia Hu","CONTACT","0086-13524945287","jiajiahu@shsmu.edu.cn",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine","RECRUITING","Shanghai","Shanghai Municipality","200025","China","CN",{"type":28,"coordinates":29},"Point",[30,31],121.45806,31.22222,{"lat":31,"lon":30},[34,38],{"name":35,"role":15,"phone":36,"phoneExt":10,"email":37},"Feng Ye","0086-13916720995","yf12110@rjh.com.cn",{"name":39,"role":15,"phone":10,"phoneExt":10,"email":10},"Biao Li",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Hu Jiajia","Deputy Director","100562005","the-value-of-68ga-grazytracer-pet-in-monitoring-responses-to-immunotherapy-of-advanced-hepatobiliary-malignancy-100562005",false,"NCT06597539","The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy","A Prospective Study on Investigating the Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy","Inclusion Criteria:\n\n1. Pathological and clinical diagnosis of advanced hepatobiliary malignancy requiring immunotherapy or combination immunotherapy after evaluation according to clinical guidelines\n2. Signed and dated informed consent form\n3. Commitment to comply with research procedures and co-operation in the implementation of the full research process\n4. aged 18-75 years old\n5. The patient is in good general condition with an expected survival of \\> 6 months\n\nExclusion Criteria:\n\n1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.\n2. Intestinal perforation, complete intestinal obstruction\n3. Uncontrolled diabetes patients or fasting blood glucose levels ≥11 mmol\u002FL on the day of the trial\n4. Pregnant women and women who may be pregnant, women who are breastfeeding.\n5. Non-compliant person","ALL","18 Years","75 Years",{"count":55,"type":56},40,"ESTIMATED","1 Year","OBSERVATIONAL","This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced hepatobiliary malignancies.",[61],"Hepatobiliary Malignancy",[63,64,65],"68Ga-grazytracer PET\u002FCT","Immunotherapy","Advanced hepatobiliary malignancy","2024-12-09",{"date":68,"type":69},"2024-12-11","ACTUAL",{"date":71,"type":69},"2024-11-09",{"date":73,"type":56},"2027-07-31",{"name":5,"class":6},1]